Skip to content

PP&E (Net) at other companies

Pfizer logo
PfizerPFE
$19.4B+5.8%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$958.07M-7.2%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$52.74M-11.3%
Insmed logo
InsmedINSM
$102.85M+16.4%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$28.5M+365%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$994K-19.8%

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s PP&E (net)?
Sarepta Therapeutics, Inc. (SRPT) reported PP&E (net) of $336.24M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s PP&E (net) changed year-over-year?
Sarepta Therapeutics, Inc.'s PP&E (net) decreased by 6.8% year-over-year, from $360.59M to $336.24M.
What is the long-term trend for Sarepta Therapeutics, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s PP&E (net) has grown at a 12.6% compound annual growth rate (CAGR), from $190.43M to $345.13M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.